Back to Search
Start Over
Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT
- Source :
- International Journal of COPD, Vol Volume 14, Pp 479-491 (2019)
- Publication Year :
- 2019
- Publisher :
- Dove Medical Press, 2019.
-
Abstract
- Anthony D D’Urzo,1 Dave Singh,2 James F Donohue,3 Edward M Kerwin,4 Anna Ribera,5 Eduard Molins,5 Ferran Chuecos,5 Diana Jarreta,5 Esther Garcia Gil5 1Department of Family and Community Medicine, Faculty of Medicine, University of Toronto, Toronto, ON, Canada; 2Medicines Evaluation Unit, Manchester University NHS Foundation Trust, Manchester, UK; 3Division of Pulmonary Diseases & Critical Care Medicine, University of North Carolina School of Medicine at Chapel Hill, Chapel Hill, NC, USA; 4Clinical Research Institute of Southern Oregon, Medford, OR, USA; 5AstraZeneca, Barcelona, Spain Background: Aclidinium/formoterol 400/12 µg is a twice-daily maintenance bronchodilator for COPD. This post hoc study evaluated aclidinium/formoterol vs aclidinium 400 µg, formoterol 12 µg, or placebo in patient subgroups. Patients and methods: Data were pooled from two 24-week Phase III clinical trials (ACLIFORM and AUGMENT). Patients (N=3,394) were analyzed by baseline airflow obstruction severity (moderate/severe), age (
- Subjects :
- COPD
aclidinium
formoterol
Diseases of the respiratory system
RC705-779
Subjects
Details
- Language :
- English
- ISSN :
- 11782005
- Volume :
- ume 14
- Database :
- Directory of Open Access Journals
- Journal :
- International Journal of COPD
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.14967ec20d684940985c8acc51931b02
- Document Type :
- article